Drugs / SCM-AGH
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04179760 | Mar 2020 → Aug 2022 | atopic eczema | SCM Lifescience Co., LTD. | Completed | No outcome recorded |
| Phase 1/2 | NCT04189419 | Aug 2019 → Jan 2022 | acute pancreatitis | SCM Lifescience Co., LTD. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCM-AGH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04179760 ↗ |
| Modality | Cell therapy | “Ingredient: Allogeneic human bone marrow-derived mesenchymal stem cells” NCT04179760 ↗ |
| Route | Intravenous | “by IV infusion” NCT04179760 ↗ |